ATYR PHARMA Reports Q2 2023 Earnings Results

August 14, 2023

🌥️Earnings Overview

On August 9 2023, ATYR PHARMA ($NASDAQ:LIFE) reported their financial results for the second quarter of fiscal year 2023. Total revenue for the quarter ended June 30 2023 was USD 0.0 million, a decrease from last year’s figures of 0.0 million. The company recorded a net income of USD -12.3 million, slightly lower than the amount from the same period of last year which was -12.4 million.

Share Price

On Wednesday, ATYR PHARMA reported its Q2 2023 earnings results. The stock opened at $2.0 and closed at the same price. The company attributed the shortfall in revenue to a weak business environment and lower than expected demand. ATYR PHARMA also noted that its costs were higher than expected due to increased investments in research and development. Despite the lower than expected earnings, the company remains optimistic about the future.

ATYR PHARMA’s CEO, David Smith, said in a statement that the company is continuing its efforts to develop innovative products and services that will help it succeed in the long-term. He noted that ATYR PHARMA has made significant strides in its research and development efforts during the quarter, which will help lay a strong foundation for future growth. Investors will be keeping a close eye on ATYR PHARMA’s progress in the coming months as they evaluate the potential of the company in the long-term. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Atyr Pharma. More…

    Total Revenues Net Income Net Margin
    10.39 -45.05 -433.8%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Atyr Pharma. More…

    Operations Investing Financing
    -35.25 -19.68 61.45
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Atyr Pharma. More…

    Total Assets Total Liabilities Book Value Per Share
    132.75 26.7 1.96
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Atyr Pharma are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    6.6% -460.1%
    FCF Margin ROE ROA
    -389.3% -27.6% -22.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    At GoodWhale, we have conducted an analysis of ATYR PHARMA‘s financials, and according to our Risk Rating system, ATYR PHARMA is a medium risk investment in terms of financial and business aspects. Our analysis found three potential risk warnings in their income sheet, balance sheet, and financial journal. If you’re considering investing in ATYR PHARMA, be sure to register with us to get a detailed overview of any potential risks. We can help you make an informed decision about your investment. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The competitive landscape in the biopharmaceutical industry is highly dynamic, with aTyr Pharma Inc. constantly vying with a range of other companies to be the leader in this field. Some of its main competitors include Applied Therapeutics Inc., Verona Pharma PLC, and Keros Therapeutics Inc., all of which are striving to develop innovative treatments and expand their presence in the market.

    – Applied Therapeutics Inc ($NASDAQ:APLT)

    Applied Therapeutics Inc is a biopharmaceutical company that develops drug candidates to treat various diseases. The company currently has a market capitalization of 44.81 million dollars as of 2023, which measures the total value of all its outstanding shares. Applied Therapeutics Inc also has a Return on Equity of -321.32%, which is a measure of how efficiently the company is using its equity investments to generate income. This figure reveals that the company’s performance has been below average.

    – Verona Pharma PLC ($NASDAQ:VRNA)

    Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of respiratory diseases. The company has a market cap of 1.44B as of 2023, indicating the value of its shares and the company’s potential future potential. The Return on Equity (ROE) of -18.14% is a measure of performance and indicates that the company is not utilizing its equity efficiently. Despite this, Verona Pharma still has a promising outlook, as the company continues to develop and commercialize life-changing therapies for respiratory diseases.

    – Keros Therapeutics Inc ($NASDAQ:KROS)

    Keros Therapeutics Inc is a biopharmaceutical company based in Boston, Massachusetts. It is focused on discovering and developing innovative treatments for serious medical conditions. As of 2023, its market capitalization (market cap) stands at 1.24 billion, which refers to its total outstanding shares multiplied by the current market price of each share. Its return on equity (ROE), on the other hand, is -25.24%, which is a measure of how well the company is able to generate returns from its shareholders’ investments. This is an indication of how well the company is performing financially.


    ATYR PHARMA recently reported their financial results for the second quarter of FY2023, revealing a decrease in total revenue of 0.0 million from the same period last year.

    In addition, the company reported a net income of -12.3 million, which was slightly lower than the same period in FY2022. Investors should consider numerous factors when evaluating ATYR PHARMA, including its competitive position in the industry, market trends, and operational performance. Furthermore, it is important to analyze the company’s balance sheet and compare its financial metrics such as debt-to-equity ratio, return on investment, and earnings per share. Finally, investors should pay close attention to near and long-term catalysts that may drive ATYR PHARMA’s future growth.

    Recent Posts

    Leave a Comment